ache, as in temporal arteritis, and also reduce NGF synthesis, which is increased by inflammation. 2 The induction of NGF activity may thus provide a new approach to prevent and treat vascular headaches.

We thank Dr D Sinicropi and Dr R Williams-Chesnut of Genentech, Inc, USA for the NGF antibody.

PANAND A PARRETT
Department of Neurology, St Bartholomew’s and Royal London School of Medicine and Dentistry, Whitechapel, London E1 2BB, UK
L CHADWICK P HAMLIN
Department of Neurosciences, St Bartholomew’s and Royal London Hospitals, London, UK

Correspondence to: Dr P Anand.


Triparich waves in serotonin syndrome

The serotonin syndrome was first described in 1960 in depressed patients with delirium due to monoamine oxidase inhibitors and L-tryptophan administration.1 Symptoms of the serotonin syndrome include mental status changes, behavioural changes, myoclonus, rigidity, hyperreflexia, and autonomic instability with low grade fevers, diaphoresis, headache, tachycardia, and pupillary dilatation.2 The serotonin syndrome has been noted to occur with several serotonergic agents, particularly when multiple agents are used.3

Psychiatry and pharmacology literature has described the serotonin syndrome for several years. As the use of serotonin reuptake inhibitors has increased, cases have begun to appear in the neurology literature—often associated with combination regimens that include serotonin reuptake inhibitors and dopaminergic agents. These cases have been attributed to the serotonergic effects of dopamine and its agonists. I describe a patient admitted for acute confusion who met criteria for the serotonin syndrome, responded well to supportive care, and whose EEG showed prominent triparich activity.

A 76 year old man had a history of Parkinson’s disease, recurrent depression, chronic constipation, and non-insulin dependent diabetes mellitus. He had received doses of 1500 mg per day of Sinemet for 10 years. He was admitted to Mayfield Hospital, Baltimore, for delirium with fever, rigidity, and movement disorder. He had not received any neuroleptic or antibiotic drugs in the previous 6 months. Electrolytes, creatinine, liver function tests, complete blood count, and ammonia concentration were all normal. Blood cultures and urinalysis were also unremarkable. A 16 channel EEG was obtained and showed pronounced triparich wave activity and diffuse slowing. Supportive care with intravenous fluids and acetaminophen was initiated and all outpatient medications were stopped. Within 24 hours the patient’s myoclonus began to subside and in 48 hours he had returned to his baseline without any sequelae. He continues to do well on Sinemet alone for his Parkinson’s disease.

Case reports of the serotonin syndrome have noted EEG abnormalities—delta range activity, slow waves, spike and waves, and polyspike and waves—but triparich waves have not previously been reported.1,4 The diagnosis of the serotonin syndrome in Parkinson’s disease population is a difficult one as many of the features of the serotonin syndrome are present in Parkinson’s disease alone. A high level of suspicion for the serotonin syndrome in patients with Parkinson’s disease taking serotonin reuptake inhibitors is necessary to make the diagnosis. Electroencephalography may play an important part in the diagnosis of the serotonin syndrome, particularly in the setting of other concurrent neurological disease.

G L DIKE
Department of Neurology, Johns Hopkins Hospital, 600 N Wolfe Street, Baltimore MD 21287, USA


Pseudoseizures or non-epileptic seizures (NES): 15 synonyms

Medical jargon is often confusing, particularly when the condition described falls within the domain of two abnormalities. This confusion reaches its zenith with those seizure disorders that do not have an epileptic aetiology. There are at least 15 synonyms for a condition that occurs in 10% to 26% of adults investigated for refractory seizures. This causes confusion for patients, doctors, and researchers. The adoption of a common term must be the rational way forward, but which one to choose?

The label pseudoseizures is the most commonly used. Its great weakness is that it is not acceptable to patients as the label implies that the seizures are not real. The reality of the "fit" is seldom an abstraction. The label pseudosepileptic seizures is both less well known and pejorative. Labels that are offensive to patients are counterproductive and best avoided.

The aetiology of this disorder is currently a matter for speculation. Terms that imply a psychological causation are misleading. Psychogenic seizures, hysterical seizures, psychogenic attacks, and hysterical attacks are all inappropriate for this reason.

A good descriptive label is non-epileptic attacks but this is seldom used. Non-epileptic attack disorder (NEAD) is rarely used and is complicated. Functional seizures, hysterosepilepsy, pseudosepilepsy, hysterical epilepsy, pseudosepileptic attacks, and psychoseizures are the least commonly used terms. These labels should all be abandoned.

This leaves the term non-epileptic seizures (NES) as the favoured candidate; it is non-judgmental, often used, acceptable to patients, and best describes the problem without implying causation.

DAVID A SCULL
Institute of Neurology, Queen Square, London WC1N 3BG, UK


Multiple sclerosis: longitudinal measurement of interleukin-1 receptor antagonist

Inflammatory activity in multiple sclerosis is regulated by a network of proinflammatory and antiinflammatory cytokines. Identifying downregulatory cytokines opens new potential therapeutic options in multiple sclerosis.1 The interleukin-1 receptor antagonist (IL-1ra) is the only known naturally occurring specific antagonistic cytokine; IL-1ra competes with IL-1 for receptor binding and lacks agonist activity. IL-1ra has been implicated in the pathogenesis of stroke and several inflammatory diseases.1 Human IL-1ra is available as a recombinant protein; the first controlled study using IL-1ra for therapy (in
relapses were in procedure (increase clinical A
sion enzyme without Tesla, were 1/3
examination with matory but consistently
humans-is multiple sepsis) was published recently. Its agonist,
Il-1β—the predominant Il-1 isoform in humans—is consistently expressed in acute multiple sclerosis plaques. It is conceivable, but so far neither confirmed nor disproved, that the natural specific antagonist Il-1ra is involved in the counterregulation of inflammatory activity in multiple sclerosis. If we would assume, Il-1ra would be a novel candidate for immunomodulatory therapy in multiple sclerosis.

We conducted a pilot study of nine patients with definite multiple sclerosis. The patients were followed up for one year by clinical examination (EDSS) and MRI every three to four weeks (resulting in 14 time points with code numbers 1 to 14), in parallel to measuring Il-1β and Il-1ra concentrations in serum and CSF. Five patients with a relapsing-remitting multiple sclerosis (two men, three women; ages 27–34; duration of disease one to three years), and four patients with chronic progressive multiple sclerosis (one man, three women; ages 40–59; duration of disease five to 28 years) were studied. Cranial MRI (Siemens Magnetom 1.0 Tesla, München, Germany) images were obtained according to standard guidelines. They were T2 and T1 weighted, with and without 0.1 mmol/kg Gd-DTPA enhancement. Serum (n = 118) and CSF samples (n = 33) were frozen within two hours of collection and stored at –80°C. Il-1β and Il-1ra were measured by commercially available enzyme linked immunosorbent assay (ELISA) kits (R and D Systems, Minneapolis, MN; sensitivity 1 pg/ml for Il-1β and 20 pg/ml for Il-1ra; intra-assay precision < 8.5%). The assays were performed in a blinded fashion, one assay for each patient. A clinical relapse was defined as an increase by > 1.0 EDSS point. A relative MRI maxi-
mum was defined as a time point with > 1 Gd enhancing lesion if preceded and followed by less MRI activity. Serum Il-1ra concentrations were individually defined as extremes (> 3 box lengths from upper boundary) using individual box plots for each patient (box length between 25th and 75th percentile) according to the SPSS pro-
cedure “boxplot”. The association between changes in Il-1ra concentrations and MRI activity was tested with the sign test (increase or decrease of Il-1ra concentration or number of active MRI lesions between two time points).

Relative MRI maxima and clinical relapses were only seen in the group of patients with relapsing-remitting multiple sclerosis, not in the one with chronic-prog-
rressive multiple sclerosis. Il-1β was not detectable in serum (n = 118 samples) or CSF (n = 33 samples). Il-1ra could be detected in all serum samples, but not in CSF. Hence serum Il-1ra concentrations were subject to further analysis. The median serum Il-1ra concentrations varied individually (range 45–422 pg/ml), but were all well above the minimal detection limit. In the one patient with the highest total number (64) of Gd enhancing lesions (patient 1), an increase or decrease of MRI activity was followed by an increase or decrease of Il-1ra concentrations by three to four weeks (one time point, P < 0.05 in sign test, figure). Individually defined extreme Il-1ra concentra-
tions were only seen in patients with relapsing-remitting multiple sclerosis. There were four such extreme concentrations in four different patients. Two of those coinci-
ded with relative maxima of MRI activity, and one with a clinical (spinal) relapse.

Smaller increases in serum Il-1ra concentrations Il-
1ra were not specific for multiple sclerosis activity, as they were also found in the group of patients with chronic-progressive multiple sclerosis and MRI activity in the observation period. This is probably due to the fact that Il-1 and Il-1ra are involved in a wide range of inflammatory activities. The longitudinal design including monthly visits proved to be too short for detecting individual extreme Il-1ra peaks. Because of the few patients, a significant association could be shown in only one patient. In her, the very high disease load (demonstrated by MRI activity) probably allowed us to detect this association. We could not detect Il-1ra in CSF, or Il-1β in CSF or serum, probably because the concentrations were below the detection limit of our ELISA assays. Because the biologically active concentration of Il-1ra is at least one magnitude higher than that of Il-1, Il-1ra may be more easily detectable than Il-1.

In conclusion, we found that fluctuations of Il-1ra may be associated with multiple sclerosis activity. The role of Il-1ra in multiple sclerosis therefore warrants further study.

Raymond Volzt
Mathias Hartmann
Johanne Spuler
Norbert Mai
Reinhard Hoehfeld
Department of Neurology, Klinikum Großenhain, University of Technology, Dresden, Germany

Correspondence to: Dr Volzt, Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York 10021, USA.

2. Olson T. Critical influences of the cytoxic orchestra on the outcome of myelin anti-
gens-specific T-cell autoimmunity in experimen-
tial autoimmune encephalomyelitis and multiple sclerosis. Immunol Rev 1995;144:
245–68.

Pathophysiology of the intermediate syndrome of organophosphorus poisoning

We report a patient with the intermediate syndrome with respiratory failure and repetitive stimulation studies and single fibre EMG. A hypothesis for the pathophysiology of the intermediate syndrome is proposed.

A 28 year old previously healthy Asian woman drank a bottle of insecticide (probably about 60 ml). She was admitted swiftly to hospital and treated with gastric lavage and intravenous atropine and a single dose of pralidoxime. After three to four days she developed respiratory weakness and was unable to lift her head. On the fifth day her vital capacity fell. Her facial muscles were weak, as was shoulder abduction and hip flexion. The distal muscles were normal. She had normal reflexes and no sensory deficit. She was intubated, respirated, and atropine was continued.

Her muscle strength slowly improved and she was weaned from the respirator on the 15th day she was neurologically normal. Neuropsychological studies were carried out on the 7th, 14th, and 18th days. She recovered completely after three weeks. Results from motor and sensory weakness and neuropsychological studies on the median nerve on the 18th day were normal.

Repetitive nerve stimulation of the ulnar nerve was carried out prior to a single recording from the abductor digiti minimi. On day 7 a single stimulus produced a repetitive discharge but the second and subsequent stimuli did not (figure). The repeti-
tive discharge was present at every stimulation with rates at 1/2s but not at 3/s. It was pre-
sent when the trial stimulus followed a few seconds after tetanus at 20/s for five sec-
onds. No decremental responses were seen at rates up to 50/s; nor was a decrement pre-
sent after one minute of exercise or after 10 seconds of repetitive stimulation at 20/s or 50/s. Incremental responses were not seen. Single fibre EMG from the clinically normal extensor digitorum communis showed two single fibre pairs with borderline jitter values; the mean consecutive difference (MCD) was 59 and 61 ms (figure). Frontalis muscle was examined on day 7 and showed increased jitter with blocking. Of 17 fibre pairs, 12 had increased jitter and seven of these had greater than 10% block-
ing (figure). As expected, blocking was only seen in pairs with a considerably raised MCD.

The intermediate syndrome follows the acute cholinergic crisis of organophosphorus poisoning and is seen in up to 20–50% of cases depending on the severity of poisoning and duration, and on the type of organophosphorus compound. It differs from myasthenia gravis in that it is a constant rather than progressive weakness, responds adversely to neostigmine, and recovers within 18 days. There are no associated autoimmune phenomena. Deductive reasoning that repetitive nerve stimulation have been seen sometimes but usually it has been the clinically unaffected peripheral muscles that were studied.

We propose that down regulation of acetylcholine receptors (AChRs) could explain the syndrome and neurophysiologi-
cal findings. These receptors have a half life of 10 days before undergoing endocytosis and proteolysis with a rate of about five per day. Regulation of the number of AChRs and
Multiple sclerosis: longitudinal measurement of interleukin-1 receptor antagonist.

R Voltz, M Hartmann, S Spuler, et al.

*J Neurol Neurosurg Psychiatry* 1997 62: 200-201
doi: 10.1136/jnnp.62.2.200-b

Updated information and services can be found at:
http://jnnp.bmj.com/content/62/2/200.3.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/